AbbVie could be heading for its second acquisition in the space of a month, with reports emerging of late-stage negotiations with Gilgamesh Pharmaceuticals, a central nervous system (CNS) drug ...
Less than a month after reports of takeover talks between AbbVie and Gilgamesh Pharma first emerged, the pair have gone public with details of a $1.2 billion deal – but it is not an acquisition. It ...
AbbVie will pay up to US$1.2 billion to acquire Gilgamesh’s short-acting psychedelic bretisilocin, highlighting growing industry interest in hallucinogenic drugs for the treatment of psychiatric ...
Gilgamesh Brewing started in 2009 by three brothers and their father in Turner. They opened their first restaurant and pub in 2012 in southeast Salem. From 2019 to 2024, they opened three more ...
AbbVie (NYSE:ABBV) has agreed to acquire from Gilgamesh Pharmaceuticals its lead investigational candidate, Bretisilocin, for up to $1.2 billion. The deal includes upfront payment plus development ...
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. AbbVie plans to buy Gilgamesh Pharmaceuticals' lead ...
NORTH CHICAGO, Ill. and NEW YORK, Aug. 25, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. ("Gilgamesh") today announced a definitive agreement under which AbbVie will ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. AbbVie on Monday said it ...
AbbVie acquires bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion, enhancing its psychiatric care portfolio. Gilgamesh will spin out a new entity to retain its remaining programs ...
In another deal between the two companies that could be worth more than $1 billion, Abbvie Inc. is buying Gilgamesh Pharmaceuticals Inc.’s lead candidate bretisilocin for up to $1.2 billion, including ...
AbbVie’s (NYSE:ABBV) move to buy New York-based psychedelic drug developer Gilgamesh Pharmaceuticals in a deal worth around $1B, according to Bloomberg News, rallied the psychedelic space on Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results